Ehab L. Atallah, MD | Froedtert & the ...

Dr. Ehab L. Atallah

Claim this profile

Froedtert Hospital & the Medical College of Wisconsin

Studies Chronic Myeloid Leukemia
Studies Chronic Illness
14 reported clinical trials
38 drugs studied

Area of expertise

1

Chronic Myeloid Leukemia

Ehab L. Atallah has run 6 trials for Chronic Myeloid Leukemia. Some of their research focus areas include:

b3a2 (e14a2) positive
b2a2 (e13a2) positive
BCR-ABL1 positive
2

Chronic Illness

Ehab L. Atallah has run 6 trials for Chronic Illness. Some of their research focus areas include:

b3a2 (e14a2) positive
b2a2 (e13a2) positive
BCR-ABL1 positive

Affiliated Hospitals

Image of trial facility.

Froedtert Hospital & The Medical College Of Wisconsin

Image of trial facility.

Medical College Of Wisconsin

Clinical Trials Ehab L. Atallah is currently running

Image of trial facility.

Screening Tool

for Myeloid Cancer

This MyeloMATCH Master Screening and Reassessment Protocol (MSRP) evaluates the use of a screening tool and specific laboratory tests to help improve participants' ability to register to clinical trials throughout the course of their myeloid cancer (acute myeloid leukemia or myelodysplastic syndrome) treatment. This study involves testing patients' bone marrow and blood for certain biomarkers. A biomarker (sometimes called a marker) is any molecule in the body that can be measured. Doctors look at markers to learn what is happening in the body. Knowing about certain markers can give doctors more information about what is driving the cancer and how to treat it. Testing patients' bone marrow and blood will show doctors if patients have markers that specific drugs can target. The marker testing in this study will let doctors know if they can match patients with a treatment study (myeloMATCH clinical trial) that tests treatment for the type of cancer they have or continue standard of care treatment with their doctor on the Tier Advancement Pathway (TAP).

Recruiting

0 awards

Phase 2

1 criteria

Image of trial facility.

Asciminib + Imatinib

for Chronic Myeloid Leukemia

This is a single arm phase II study that will enroll a minimum of 47 subjects with a maximum of 51. All patients will have a confirmed diagnosis of chronic phase chronic myeloid Leukemia and must have previously attempted to discontinue Tyrosine Kinase inhibitors (TKI). All patients must have restarted the same TKI they were on prior to discontinuation at the time of relapse in order to be eligible for this trial.

Recruiting

1 award

Phase 2

20 criteria

More about Ehab L. Atallah

Clinical Trial Related

7 years of experience running clinical trials · Led 14 trials as a Principal Investigator · 3 Active Clinical Trials

Treatments Ehab L. Atallah has experience with

  • Asciminib
  • Venetoclax
  • Dasatinib
  • Imatinib
  • Nilotinib
  • Azacitidine

Other Doctors you might be interested in

Frequently asked questions

Do I need insurance to participate in a trial?

What does Ehab L. Atallah specialize in?

Is Ehab L. Atallah currently recruiting for clinical trials?

Are there any treatments that Ehab L. Atallah has studied deeply?

What is the best way to schedule an appointment with Ehab L. Atallah?

What is the office address of Ehab L. Atallah?

Is there any support for travel costs?